Wacker Biotech GmbH has an established track record in process development and contract-manufacturing of recombinant proteins. We hold GMP certificates for the production of recombinant proteins. Our customers are international, both large and small pharmaceutical and biotech companies.

Our expertise includes:

• Fast construction and optimization of vector systems
• ESETEC^®: Proprietary E. coli secretion technology for the secretion of proteins in native conformation into the fermentation medium
• Production and characterization of master and working cell banks
• Efficient process development and optimization
• GMP-compliant production facility
• DENSETEC^®:Proprietary technology for high-cell-density fermentation
• Process scale from 20 liters to 300 liters (expansion planned)
• Development and validation of analytical methods for process control and final product characterization
• Broad range of purification technologies (DSP)
• PEGylation of proteins
• Careful process validation including comprehensive documentation

Wacker Biotech’s experience with therapeutic proteins dates back to the 1980s, when the key focus was on developing interferon alpha. Biopharmaceuticals have been commercially developed and produced since 1999. Back then, Wacker Biotech GmbH – formerly known as ProThera GmbH – was established as a spin-off of the state-owned Hans Knöll Institute in Jena. The company has been a wholly-owned subsidiary of Wacker Chemie AG since January 2005. WACKER has been working with industrial biotechnology processes since the 1980s, has been a provider of contract chemical synthesis services to the pharmaceutical industry for many decades.